Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Pralatrexate is a type of antifolate drug which means is restrains the production of folic acid in the body. Folic acids are used by tumors to increase tumor cell growth and division.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01188876
- Testing
- carboplatin, pralatrexate, Folic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Ovarian Neoplasm, Chemotherapeutic Toxicity
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Observational, clinical study. Intention to include 40 patients (20 patients treated with trabectedin and 20 with cisplatin hypersensitivity) The investigators investigate the role of trabectedin in combination with PLD and…
- Conditions
- Ovarian Neoplasm, Chemotherapeutic Toxicity, Chemotherapy Effect, Chemotherapy-induced Neutropenia
- Trial name
- TvsCH (NCT05512676)
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Ovarian Cancer
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Many ovarian cancer patients have been offered different standard cytostatics and gradually develop chemo-resistance. However, a considerable fraction of these patients are still in good general health and have a strong wish for…
- Trial name
- CaTo-ROC (NCT02560337)
- Testing
- Cabazitaxel
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Vejle Hospital
Breast Cancer, Ovarian Cancer
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence.
- Trial name
- NCT06430541
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Ovarian Cancer, Peritoneal Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05071937
- Testing
- ZEN003694, Talazoparib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Alexander B Olawaiye, MD
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I clinical trial studies the side effects of vaccine therapy and cyclophosphamide in treating patients with stage II-III breast cancer or stage II-IV ovarian, primary peritoneal or fallopian tube cancer.
- Conditions
- Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01606241
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have persistent or recurrent ovarian epithelial or primary peritoneal cancer.
- Trial name
- NCT00041041
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06161272
- Testing
- Fluzoparib, Fluzoparib+Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangxi Medical University
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus The study will also…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT03564340
- Testing
- Ubamatamab, Cemiplimab, Sarilumab
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 890 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Cancer, Fallopian Tube
Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
The purpose of this study is to see if Positron Emission Tomography (PET) probes make it easier for your surgeon to find cancer and remove it during your surgery. A PET probe is a wandlike device that can detect radioactivity.
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal
- Trial name
- NCT01826227
- Testing
- Positron Emission Tomography, 18F-Fluoro-2-deoxy-D-lucose, Cytoreductive surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and…
- Trial name
- NCT01567891
- Testing
- NYESO-1c259 T cells
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Adaptimmune
Ovarian Cancer, Peritoneal Cavity Cancer
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00043082
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- 91 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have…
- Trial name
- NCT00006262
- Testing
- becatecarin
- Where
- United States
- Sponsor
- Northwestern University
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of intraperitoneal interleukin-12 in treating patients who have ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00016289
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Endometrial Cancer
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
The purpose of the study is to determine if the combination of Everolimus and Letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or…
- Trial name
- NCT02188550
- Testing
- everolimus and letrozole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sinai Hospital of Baltimore
Ovarian Cancer, Cholangiocarcinoma Recurrent
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer…
- Conditions
- Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
- Trial name
- NCT05568680
- Testing
- SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Verismo Therapeutics